The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2018 | Monoclonal antibodies: current and future potential
Approved monoclonal antibodies for multiple myeloma (MM) are currently available, yet there are still gaps to explore in this therapeutic area for MM. At the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France, Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, discusses up-to-date clinical evidence for monoclonal antibody therapies, as well as the potential of bispecific antibodies and antibody-drug conjugates in MM.
